. The management of HCV-related cryoglobulinaemic MPGN is difficult; HCV eradication by antiviral therapy with interferon-and ribavirin can lead to clinical remission [2] , but severe/active renal disease may be resistant to antiviral therapy [1] [2] [3] . In such cases, corticosteroids in combination with cytotoxic agents and plasmapheresis have been used to decrease cryoglobulin production and improve vasculitic manifestations, but long-lasting remission of the renal disease is uncommon. We report a case of severe/active HCV-related cryoglobulinaemic MPGN which was successfully treated by means of the sequential administration of immunosuppressive and antiviral agents.
A 50-year-old man presented with a 5-week history of arthralgia and ankle oedema. The physical examination on admission showed hypertension (180/100 mmHg), pleural effusion and oedema of the legs. The laboratory findings were haemoglobin 118 g/l, serum albumin 25 g/l, blood urea nitrogen 49 mg/dl and creatinine 1.6 mg/dl with creatinine clearance of 52 ml/min. Alanine (ALT) and aspartate aminotransferases (AST) levels were in the normal range. Urinalysis showed heavy proteinuria (10.5 g/24 h) and active urine sediment. The patient was positive for HCV antibodies and serum HCV RNA; the genotype was 1 and the viral load 7.6 Â 10 6 copies/ml. The other laboratory results were rheumatoid factor (RF) 871 IU/ml (0-15), complement factor C4 0.19 g/l (0.20-0.50) and cryocrit 20%, with type II (IgG-IgM-k) cryoglobulins. A liver biopsy showed mild chronic hepatitis (grade A1, stage F1 according to the METAVIR Cooperative Study Group) [4] , and a kidney biopsy a cryoglobulinaemic MPGN with marked endocapillary proliferation, intraluminal thrombi, cellular crescents and vasculitis with fibrinoid necrosis; immunofluorescence microscopy revealed granular capillary wall and mesangial deposits and intraluminal masses of IgM, IgG and C3. Immunosuppressive treatment was started with corticosteroids (methylprednisolone pulses of 1.0 g/day for 3 days, followed by oral prednisone 1.0 mg/kg/day slowly tapered to a maintenance dose of 0.2 mg/kg/day) and oral cyclophosphamide 2 mg/kg/day. After 3 months, serum creatinine and creatinine clearance had normalized, proteinuria had decreased to 800 mg/24 h and cryocrit to 5%, and the clinical signs of the disease (pleural effusion, ankle oedema, arthralgia) had disappeared. ALT and AST levels remained unchanged, whereas HCV RNA levels had increased (38.3 Â 10 6 copies/ml). As the nephrotic syndrome was in clinical remission, cyclophosphamide and prednisone were discontinued, and antiviral treatment was started with once-weekly injections of peginterferon -2a 100 mg Nephrol Dial Transplant (2006) 21: 3333-3345 combined with ribavirin 800 mg/day. Twelve weeks later, serum HCV RNA had disappeared, a result that was confirmed at the end of antiviral therapy in week 48, and during the post-treatment follow-up. Proteinuria returned to the normal range (40 mg/24 h), cryoglobulins decreased to undetectable levels and serum C4 levels normalized. RF activity decreased, but remained above normal.
Our case shows that severe/active cryoglobulinaemic MPGN can be controlled by a short course of immunosuppressive treatment and that the definitive cure of HCVrelated cryoglobulinaemic glomerulonephritis can be expected from a therapy leading to sustained viral eradication.
Although the sequential administration of immunosuppressive and antiviral drugs is a rational therapeutic approach to HCV-infected patients with acute flares of cryoglobulinaemia and glomerulonephritis, its safety and efficacy need to be confirmed in prospective clinical trials.
